申请人:Hoechst Aktiengesellschaft
公开号:US04515795A1
公开(公告)日:1985-05-07
A pharmaceutical composition containing as an essential ingredient a compound of the formula ##STR1## wherein one of the groups R.sub.1, R.sub.2 and R.sub.3 is an .omega.- or (.omega.-1)-hydroxyalkyl group having from 5 to 8 carbon atoms in which the hydroxy group is separated from the xanthine nucleus by at least 2 carbon atoms, radicals R.sub.1 and R.sub.3 which are no hydroxyalkyl group, are hydrogen or methyl and equal or different, and R.sub.2 is said hydroxyalkyl group or methyl, a compound of formula (I) and a pharmaceutical product for treatment of diseases involving insufficiency of cerebral blood flow.
一种药物组合物,其主要成分为公式##STR1##中的化合物,其中R.sub.1、R.sub.2和R.sub.3中的一个是具有5至8个碳原子的ω-或(ω-1)-羟基烷基基团,羟基团至少与黄嘌呤核之间相隔2个碳原子,基团R.sub.1和R.sub.3不是羟基烷基基团,则为氢或甲基,可以相同也可以不同,而R.sub.2是所述的羟基烷基基团或甲基,化合物的公式为(I),以及用于治疗涉及脑血流不足疾病的药物产品。